Is Cellular Biomedicine Group A Buy?

Cellular Biomedicine Group (NASDAQ:CBMG) has investment potential for a number of reasons. Its primary market, China, has at least four times the population of the United States, and has an aging population, and CBMG is interested in the US market too. Its last 10-K states that ‘stem cell products for injection into painful joints’ will fuel an overall increase in the use of US stem....More>>>

Hot Safest Stocks To Watch For 2017

Top 10 Surprising States With Most Millionaires

Retirement Is Lifes Most Expensive Purchase

Why Former Reagan Official Stockman Sees a Huge Trump Correction

The American College of Financial Services has launched a scholarship program to help boost the number of African-Americans in the financial services industry.

According to the latest data from the U.S. Bureau of....More>>>

Small Cap Bellicum Pharmaceuticals: On the Rebound

On Thursday, our Under the Radar Moversnewsletter suggestedgoing long on small cap clinical-stage biopharmaceutical cancer stock Bellicum Pharmaceuticals (NASDAQ: BLCM):

This entry is probably a little sooner than we’d normally like to get into a budding rebound. But, we’d rather be early than late this time around. As of this week, BLCM shares are above February high, further....More>>>

Apple, Inc. Reportedly Preparing to Begin Manufacturing iPhones in India”

There’s been a lot of talk over the past few months about where Apple (NASDAQ:AAPL) may or may not expand its manufacturing footprint. President Trump would naturally like it if Apple brought some manufacturing jobs back home, despite the massive cost increases that would come along with such a move. But Apple has long faced challenges with expanding sales in India in part due to a government....More>>>

Howard University campus opening at Google in diversity push

Google is trying something new to boost diversity.

The tech giant is partnering with Howard University to launch “Howard West,” a three-month summer program open to rising juniors and seniors studying computer science.

The 25 to 30 students selected for this summer’s program will be taught by senior Google engineers and Howard faculty on Google’s Mountain....More>>>

stock market training

What happened

Shares of Flexion Therapeutics (NASDAQ:FLXN) rose by more than 33% at$26.28 in Thursday trading, in response to rumors that a takeover bid from Sanofi (NYSE:SNY) is looming.

Image source: Getty Images.

So what

According to a report by Fierce Pharma, Flexion has accepted a takeover offer from the French pharma giant Sanofi.This information comes from....More>>>

SNAP Stock: Another Reason To Avoid Snap Inc. (SNAP) Stock

Is the second consecutive Buy rating a buy signal forSnap stock? Think again.
Flickr

Shares ofVenice, California-based Snap Inc (NYSE:SNAP), the parent company of popular photo-sharing app Snapchat,were upmore than 2% in the last trading session (March 21), even when the broader marketswitnessed the largest decline of the year. Thanks to a secondconsecutive buy rating. This comes as....More>>>

Top Heal Care Stocks To Invest In 2017

Income investors appreciate stocks that pay lucrative dividends, and recently, many companies have seen the value in treating shareholders well by boosting their regular payouts. Yet a few holdouts simply don’t show their appreciation for their investors through dividends. For whatever reason, rather than having no dividend at all, Joy Global (NYSE:JOY), Textron (NYSE:TXT), and Global Payments....More>>>

Top Gold Stocks For 2017

Related GLD JPMorgan's Kolanovic On Stocks, Gold And Advice For The Fed This Little Nugget Of An ETF Is Delivering Astounding Returns Take Profits In SPDR Gold Trust – NIRP Fallacy, Economic Balance, Dollar Recovery Weigh Against Gold Near-Term (Seeking Alpha)

April Gold futures are....More>>>

The Trump Trend In Stocks Has Broken Down

Over the past week, I’ve talked about the potential for disruption in what has been very smooth sailing for financial markets (led by stocks). While the picture has grown increasingly murkier, markets had been pricing in the exact opposite–which makes things even more vulnerable to a shakeout of the weak hands.

With that, it looks like we are indeed working on a correction in....More>>>